Vertex EVP Atkinson sells 668 shares under plan

Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported share sales under a pre-set trading plan.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported share sales under a pre-set trading plan. On February 25, 2026, he completed an open-market sale of 668 shares of common stock at $486.35 per share, leaving 18,432 shares held directly afterward.

On February 24, 2026, he disposed of 1,627 shares at $485.11 per share to cover tax obligations by delivering shares, a non-open-market transaction. These transactions were made under a company-approved Rule 10b5-1 trading plan that Mr. Atkinson entered into on August 11, 2025.

Insider Trade Summary

Net Seller: 668 shares

Net Sell 2 txns

Insider Atkinson Edward Morrow III

Role EVP, Chief Technical Ops. Off.

Sold 668 shs ($325K)

Type	Security	Shares	Price	Value
Sale	Common Stock	668	$486.35	$325K
Exercise Price or Tax Liability	Common Stock	1,627	$485.11	$789K

Holdings After Transaction: Common Stock — 18,432 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VRTX executive Edward Atkinson report?

Edward Morrow Atkinson III reported one open-market sale of 668 Vertex common shares and one tax-related disposition of 1,627 shares. Both transactions involved directly held stock and were executed under a pre-established Rule 10b5-1 trading plan.

How many VRTX shares did the Vertex EVP sell in the open market?

He sold 668 shares of Vertex common stock in an open-market transaction. The sale occurred at a price of $486.35 per share, and following this transaction he directly held 18,432 shares of Vertex common stock.

What was the purpose of the 1,627 VRTX shares disposed by Edward Atkinson?

The 1,627 Vertex shares were disposed of to satisfy tax obligations by delivering shares. This tax-withholding disposition, coded “F,” was not an open-market sale and was executed at $485.11 per share as part of his equity compensation.

Were Edward Atkinson’s VRTX stock transactions pre-planned under Rule 10b5-1?

Yes, both transactions were executed under a company-approved Rule 10b5-1 trading plan. The footnote states the plan was entered into on August 11, 2025, providing a pre-arranged framework for these trades.

How many VRTX shares did Edward Atkinson hold after the reported transactions?

After the February 25, 2026 open-market sale of 668 shares, Edward Atkinson directly held 18,432 Vertex common shares. Following the earlier tax-withholding disposition on February 24, 2026, he had held 19,100 shares before the subsequent sale.

What do the transaction codes S and F mean in this VRTX Form 4?

Code “S” indicates an open-market or private sale of shares, used for the 668-share sale. Code “F” indicates shares delivered to pay an exercise price or tax liability, describing the 1,627-share tax-withholding disposition on Vertex stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 06:00 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Atkinson Edward Morrow III

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Technical Ops. Off.

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		F		1,627	D	$485.11	19,100	D
Common Stock	02/25/2026		S(1)		668	D	$486.35	18,432	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.